1. 4CPS-162 Infliximab serum concentrations, antibody formation and clinical response in psoriatic patients. (2nd March 2018) Authors: Colls, M; Padullés, N; Padullés, A; Notario, J; Bas, J; Fernández, C Mariño; Colom, H Journal: European journal of hospital pharmacy Issue: Volume 25(2018)Supplement 1 Page Start: A117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 6ER-001 Association between faecal calprotectin values and infliximab trough levels in inflammatory bowel disease patients. (2nd March 2018) Authors: Santacana, E; Padullés, N; Padullés, A; Rodríguez-Alonso, L; Guardiola, J; Bas, J; Esteban-Sánchez, CM; Colom, H Journal: European journal of hospital pharmacy Issue: Volume 25(2018)Supplement 1 Page Start: A229 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P318 Association between faecal calprotectin values and infliximab trough levels in inflammatory bowel disease patients. (16th January 2018) Authors: Rodriguez Alonso, L; Serra, K; Santacana, E; Padullés, N; Arajol, C; Gilabert, P; Orobitg, J; Rodríguez-Moranta, F; Colom, H; Padullés, A; Bas, J; Guardiola, J Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S261 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P645 Pharmacokinetics and immunogenicity of Infliximab biosimilar in inflammatory bowel disease patients. (25th January 2019) Authors: Guardiola, J; Rodriguez Alonso, L; Padullés, N; Santacana, E; Serra, K; Padulles, A; Ruiz-Cerulla, A; Gilabert, P; Arajol, C; Ibañez-Sanz, G; Camps, B; Colom, H; Bas, J; Morandeira, F; Sanchez, E; Orobitg, J; Rodriguez Moranta, F Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S441 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P761 IFX dose-escalation strategy based on a population PK model in IBD patients with secondary loss of response. (16th January 2018) Authors: Guardiola, J; Rodriguez Alonso, L; Serra, K; Santacana, E; Colom, H; Rodríguez-Moranta, F; Gilabert, P; Arajol, C; Sanchez Pastor, E; Bas, J; Padullés, A; Padullés, N Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S496 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PKP-009 Evaluation of a population pharmacokinetic model of infliximab in rheumatoid arthritis for prediction of individual dosage requirements. (14th February 2016) Authors: Padullés, A; Padullés, N; Lloberas-Blanch, N; Juanola, X; Narvaez, FJ; Leiva, E; Cobo, S; Bas, J; Climent, J; Carrere, M; Colom, H Journal: European journal of hospital pharmacy Issue: Volume 23(2016)Supplement 1 Page Start: A182 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PKP-010 Impact of the RS1143634 polymorphism of interleukin 1β on infliximab exposure in crohn's disease and ulcerative colitis patients. (14th February 2016) Authors: Santacana, E; Padullés, N; Padullés, A; Padró, A; Rodríguez-Alonso, L; Guardiola, J; Bas, J; Carreres, M; Colom, H Journal: European journal of hospital pharmacy Issue: Volume 23(2016)Supplement 1 Page Start: A182 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PKP-012 Body surface area, cigarrete smoking and infliximab response in patients with psoriasi. (14th February 2016) Authors: Colls, M; Padulles, N; Padullés, A; Notario, J; Bas, J; Sanmarti, N; Colom, H Journal: European journal of hospital pharmacy Issue: Volume 23(2016)Supplement 1 Page Start: A183 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗